Previous 10 | Next 10 |
2023-09-06 18:16:56 ET More on Amneal Pharmaceuticals Seeking Alpha’s Quant Rating on Amneal Pharmaceuticals Historical earnings data for Amneal Pharmaceuticals Financial information for Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. 2023 Q2 - Res...
- Key injectable currently on the U.S. FDA shortage list - Received Competitive Generic Therapy approval designation Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application...
- 1 st product approval in China represents Amneal’s entry in second largest pharmaceutical market - Expects international expansion will be another key vector for long-term growth and impact Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the ...
- Key ADHD medicine on the U.S. FDA shortage product list - Represents another high-value product approval for Amneal Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Applicatio...
- Senior members of the U.S. Government Visit One of Amneal’s 12 Manufacturing Sites Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that a delegation of senior members of the U.S. Department of Health and Human ...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2023 Wells Fargo Healthcare Conference on September 7, 2023 in Boston. Mr. Pat...
- IPX203 demonstrated statistically significant improvement in daily “Good On” time compared to optimized IR CD/LD, with fewer daily doses Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that JAMA Neurology has published results from the RISE-PD clinical study ...
2023-08-21 16:01:59 ET Are you on the hunt for the most promising penny stocks to invest in for 2023? Join the ever-expanding group of investors who are keen to leverage the booming market. With record-breaking performances by the S&P 500 and Nasdaq this year, there’s a growi...
2023-08-07 14:08:45 ET Investors often rely on stock market news to stay abreast of everything, ranging from low-cost penny stocks to industry giants such as Apple or Tesla. It’s no secret that news can ignite excitement and skepticism in the blink of an eye, fueling speculation ...
2023-08-04 15:59:06 ET Amneal Pharmaceuticals, Inc. (AMRX) Q2 2023 Earnings Conference Call August 4, 2023 08:30 ET Company Participants Anthony DiMeo - Head, Investor Relations Chirag Patel - Co-Founder and Co-Chief Executive Officer Chintu Patel - Co-Founder an...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NYSE Market:
Amneal Pharmaceuticals Inc. Class A Website:
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...
Builds on successful U.S. biosimilar partnership of 2 oncology products (RELEUKO ® & FYLNETRA ® ) ADL018 is Kashiv’s lead pipeline biosimilar program, currently in Phase III Kashiv BioSciences, LLC (“Kashiv” or the “Companyȁ...